Nonprescription status for emergency contraception

Sibbald, Barbara
March 2005
CMAJ: Canadian Medical Association Journal;3/29/2005, Vol. 172 Issue 7, p861
Academic Journal
Reports on the possibility that emergency contraception will become available without a prescription in Canada by April 2005. Target applications of the levonorgestrel drug after unprotected sexual intercourse; Criteria of Health Canada to classify levonorgestrel as a nonprescription medication; Role of pharmacists in the decision of Health Canada.


Related Articles

  • Over-the-counter emergency contraception approved.  // WHO Drug Information;1999, Vol. 13 Issue 3, p172 

    Reports on the approval of a emergency contraception preparation containing two tablets of levonorgestrel, Norlevo, for over-the-counter marketing in France. Efficacy of levonorgestrel.

  • A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraception. Suk Wai Ngai; Susan Fan; Shiqin Li; Linan Cheng; Juhong Ding; Xiaoping Jing; Ernest Hung Yu Ng; Pak Chung Ho // Human Reproduction;Jan2005, Vol. 20 Issue 1, p307 

    BACKGROUND: Levonorgestrel (0.75 mg given for two doses 12 h apart) has been proven to be an effective regimen for emergency contraception when the first dose is given within 72 h of unprotected coitus. However, the dosing interval is inconvenient for those taking the first...

  • Emergency contraception: Is it time to change method? Webb, Anne // BMJ: British Medical Journal (International Edition);02/06/99, Vol. 318 Issue 7180, p342 

    Features levonorgestrel as an emergency contraception method and as an alternative of combined estrogen-progestogen method. Effectiveness of levonorgestrel; How to avail and use the pill; Issues about the use of contraceptives.

  • New Long-Acting Contraceptive Can Also Help Women Avoid Hysterectomy.  // HealthFacts;Mar2001, Vol. 26 Issue 3, p4 

    Reports on the effectiveness of the intrauterine device, called Mirena, on birth control and an alternative to hysterectomy for women who suffer excessive menstrual flow.

  • ULIPRISTAL ACETATE- A NOVEL ORAL EMERGENCY CONTRACEPTIVE: HYPE OR HOPE? Ghatak, Somsuvra B.; Panchal, Shital J. // International Journal of Pharmaceutical Sciences Review & Resear;Sep2010, Vol. 4 Issue 3, p152 

    Unintended pregnancy is a global reproductive health concern. Although emergency contraception is meant to be used after an unprotected intercourse to prevent unwarranted pregnancies, available methods including levonorgestrel 1·5 mg, the currently gold standard EC regimen, is only effective...

  • Association between levonorgestrel emergency contraception and the risk of ectopic pregnancy: a multicenter case-control study. Zhang, Jian; Li, Cheng; Zhao, Wei-Hong; Xi, Xiaowei; Cao, Shu-Jun; Ping, Hua; Qin, Guo-Juan; Cheng, Linan; Huang, He-Feng // Scientific Reports;2/13/2015, p8487 

    Cases of ectopic pregnancy (EP) following levonorgestrel emergency contraception (LNG-EC) failure have been reported continuously, but whether there is an association between EP risk and LNG-EC is unclear. We concluded a case-control study to explore this association by recruiting 2,411 EP...

  • OTC status looks likely for Plan B in Canada.  // PharmacoEconomics & Outcomes News;5/17/2008, Issue 553, p10 

    The article reports on the recommendation by the national Drug Scheduling Advisory Committee to make emergency contraceptive levonorgestrel an over the counter (OTC) drug in Canada. According to a report in the May 2008 issue of the "British Journal of Medicine," the National Association of...

  • Plan B OTC: Not a total solution. Zarbock, Sarah // Pharmacy Today;May2007, Vol. 13 Issue 5, p25 

    The article reports on the approval by the Food and Drug Administration (FDA) on the sale Plan B or levonorgestrel—B without a prescription in the U.S. The over-the-counter (OTC) drug was shipped to pharmacies, enabling American women older than 18 years to gain access to emergency...

  • Playing politics: with women's health: The FDA and Plan B. Greene, Michael F.; Lockwood, Charles J. // Contemporary OB/GYN;Jul2004, Vol. 49 Issue 7, p11 

    The article focuses on the decision of the U.S. Food and Drug Administration not to approve the request for the over-the-counter (OTC) status of the Plan B emergency contraceptive (EC) drug by Barr Pharmaceuticals. The drug is consist of two 0.75 milligram levonorgestrel pills to be taken 12...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics